Printer Friendly

OncoVista Increases Its Share in AdnaGen AG.

Majority Ownership is Increased from 51% to 85% of Shares

SAN ANTONIO -- OncoVista, Inc., (OTC BB: AVUG) a biopharmaceutical company dedicated to developing innovative, safe and efficacious treatments for cancer, today announced that it has successful completed the acquisition of additional shares of AdnaGen AG (Hanover, Germany), increasing its ownership from 51% to 85% of the issued and outstanding shares of the company.

AdnaGen AG has developed a proprietary method for the detection of circulating tumor cells (CTCs) from blood. The AdnaGen technology involves immunomagnetic separation of CTCs from blood, followed by detection of tumor-associated markers using RT-PCR based molecular diagnostic techniques. The technology can be applied to a wide variety of cancer types. Currently, AdnaGen's kits are marketed in Europe for both breast cancer and colon cancer, with revenues in 2007 estimated at EU1.3 million.

The detection of CTCs may be useful in several ways. First, the presence of CTCs may serve as an early indicator of metastatic disease. Testing for CTCs also provides a way to monitor the efficacy of cancer treatments, with persistence of CTCs suggesting the need to either prolong treatment or seek alternative approaches and disappearance of CTCs suggesting response to treatment. Finally, the reappearance of CTCs at some point following an initially successful therapy may serve as an early indicator of disease relapse.

Alexander L. Weis, CEO of OncoVista, noted that "The AdnaTest technology is exciting because its integration into our clinical trials will allow us to prescreen and select patients for our studies who are most likely to respond to treatment. Additionally, monitoring for CTCs may give us an early indication of treatment efficacy."

AdnaGen recently completed preliminary studies to explore the potential of its CTC test as a prognostic marker for breast cancer. In 2008, the company plans to initiate a pivotal trial to establish the prognostic utility of its breast cancer CTC test.

AdnaGen AG is based in Hanover, Germany. The law firm of Diestel & Partner (Hamburg) assisted in the completion of the transaction.

About OncoVista, Inc.

OncoVista is a publicly traded development-stage biopharmaceutical company dedicated to providing innovative, safe and efficacious treatments for cancer. For more information, please visit

Safe Harbor Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking statements that are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. The above information does not guarantee any successful closing of new business. No assurances can be given that any projections contained herein will be realized. Forward-looking statements involve known and unknown risks and uncertainties that may cause the companies' actual results in future periods to differ materially from forecasted results. Such risks and uncertainties include, but are not limited to, market conditions, competitive factors, the ability to successfully complete additional financings and other risks.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 17, 2007
Previous Article:Mission Residential Secures $100mm Fannie Mae Debt Facility.
Next Article:Caringo Expands European Market for CAStor Single Tier Storage Environments.

Related Articles
DSM Engineering Plastic Products bv.
Software AG's Q1 Figures Give Flotation Plans a Boost.
ALTANA AG reports excellent results in 2006.
OncoVista Licenses Phase II Clinical-Stage Drug from OSI Pharmaceuticals.
OncoVista Innovative Therapies, Inc. Announces Appointment of AdnaGen Chief Executive Officer.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters